Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report

Published:2018-03-25 Issue:1 Volume:179 Page:182-185
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Thorlacius L.¹²³^ORCID,Theut Riis P.¹²^ORCID,Jemec G.B.E.¹²

Affiliation:

1. Department of Dermatology; Zealand University Hospital; Roskilde Denmark

2. Health Sciences Faculty; University of Copenhagen; Copenhagen Denmark

3. Musculoskeletal Statistics Unit; The Parker Institute, Bispebjerg and Frederiksberg Hospital; Copenhagen Denmark

Funder

Region Zealand Research Foundation

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.15769/fullpdf

Reference19 articles.

1. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β;Zee;Br J Dermatol,2011

2. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa;Kelly;Br J Dermatol,2015

3. Interventions for hidradenitis suppurativa;Ingram;Cochrane Database Syst Rev,2015

4. Treatment of hidradenitis suppurativa with etanercept injection;Adams;Arch Dermatol,2010

5. Two phase 3 trials of adalimumab for hidradenitis suppurativa;Kimball;New Engl J Med,2016

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammasomes: emerging therapeutic targets in hidradenitis suppurativa?;British Journal of Dermatology;2024-06-24

2. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa;Expert Opinion on Biological Therapy;2024-04-02

3. Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study;Clinical, Cosmetic and Investigational Dermatology;2024-01

4. Treating refractory acne conglobata with secukinumab: A case report;The Journal of Dermatology;2023-09-19

5. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data;Clinical, Cosmetic and Investigational Dermatology;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3